Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057

SHIRE PLC (SHP)

Delayed Quote. Delayed  - 03/24 05:35:00 pm
4676.5 GBp   +0.25%
03/23 SHIRE : Issues 2016 Annual Responsibility Review
03/23 SHIRE : 2016 Annual Report – DTR 6.3.5 ...
03/22 SHIRE : Gets US FDA Fast Track Designation For SHP655
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2012 | 05:49pm CEST
  By Sten Stovall 
  Of  
 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE PLC
03/23 SHIRE : Issues 2016 Annual Responsibility Review
03/23 SHIRE : 2016 Annual Report – DTR 6.3.5 ...
03/22 SHIRE : Gets US FDA Fast Track Designation For SHP655
03/18 SHIRE : s (SHPG) Cinryze Label Expanded for Pediatric Use
03/16 XENETIC BIOSCIENCES : to Present at the 29th Annual ROTH Conference
03/13DJSHIRE : Files 8K - Other Events
03/13 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
03/10 SHIRE PLC (NASDAQ : SHPG) Files An 8-K Other Events
03/10DJSHIRE : Files 8K - Other Events
03/10 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/26 FOCUS ON EUROPE : Who Earned A $250M Performance Bonus Last Week?
03/22 Shire's SHP655 Fast Track'd for rare enzyme deficiency
03/18 It's Time To Buy Shire
03/16 Expanded use of Shire's CINRYZE OK'd in Europe
03/14 My Favorite Millennial's Dividend Growth Portfolio
Advertisement
Financials ($)
Sales 2017 15 256 M
EBIT 2017 5 841 M
Net income 2017 2 850 M
Debt 2017 18 339 M
Yield 2017 0,62%
P/E ratio 2017 15,64
P/E ratio 2018 11,99
EV / Sales 2017 4,68x
EV / Sales 2018 4,08x
Capitalization 52 993 M
More Financials
Chart SHIRE PLC
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 73,4 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
David R. Ginsburg Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC-0.16%52 993
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results